Event Details
Dates: November 5–6, 2026
Event Website: 2026 Global Colorectal Cancer Congress
Event Overview
Cizzle Bio will attend the 2026 Global Colorectal Cancer Congress, taking place November 5–6 in a worldwide virtual access.
Hosted by the Global Colon Cancer Association (GCCA), the Congress is an international forum dedicated to advancing colorectal cancer advocacy, education, research, and collaboration. Patient advocates, healthcare professionals, researchers, policymakers, and industry partners will come together to exchange practical insights and examine developments shaping colorectal cancer prevention, diagnosis, treatment, and care.
Registration includes access to live virtual sessions and on-demand recordings after the Congress. Simultaneous translation will be available in more than 60 languages, helping make the program accessible to participants around the world. GCCA membership is not required to attend.
Congress Topics
The 2026 program will explore key issues across the colorectal cancer continuum, including:
Prevention, risk reduction, and screening to identify colorectal cancer earlier.
Biomarkers, precision medicine, and diagnostics supporting better-informed treatment decisions.
The responsible use of artificial intelligence for clinicians, patients, and caregivers.
Equity, access, and health-system capacity, with a focus on underserved communities.
Patient experience, survivorship, and supportive care beyond diagnosis.
Advocacy, policy, and global collaboration to create sustainable system-level change.
Why Attend
Learn from international experts and advocates working across colorectal cancer prevention, care, research, and policy.
Explore developments in screening, biomarkers, precision medicine, diagnostics, and artificial intelligence.
Gain perspectives on improving equity, access, patient experience, and health-system capacity.
Connect with a global community representing healthcare, research, advocacy, government, and industry.
Access session recordings after the Congress for continued learning.
Cizzle Bio’s Focus
As a company advancing biomarker blood tests for early cancer detection, Cizzle Bio values opportunities to engage with global leaders working to improve how cancers are prevented, detected, diagnosed, and managed.
Attending the Global Colorectal Cancer Congress supports our commitment to learning from advances in screening, biomarker science, precision diagnostics, health equity, and patient-centered care. We look forward to participating in conversations that strengthen international collaboration and help move earlier detection and better cancer outcomes forward.